Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.64 |
| ▸ | FNTB | P49356 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.43 |
| ▸ | SQLE | Q14534 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297989 | 1.00 | FNTA (0.64) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL14826006 | 1.00 | FNTA (0.64) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL14815134 | 1.00 | FNTA (0.64) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL10297987 | 1.00 | FNTA (0.64) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL8970580 | 0.91 | FNTA (0.73) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL8970577 | 0.91 | FNTA (0.73) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL16125781 | 0.88 | FNTA (0.60) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL14825971 | 0.87 | FNTA (0.59) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL14825968 | 0.87 | FNTA (0.59) | FNTAFNTBALDH1A1ALOX15KMT2A | |
| SCHEMBL22466380 | 0.86 | FNTA (0.66) | FNTAFNTBALDH1A1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150133431-A1 | GGA DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133431-A1 | GGA DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140275282-A1 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013130654-A1 | GGA AND GGA DERIVATIVES, COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013052148-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
| US-20120172453-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | COYOTE PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172453-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | COYOTE PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | disclosed |
| WO-2012031028-A2 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | COYOTE PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133431-A1 | GGA DERIVATIVES | PGGT1B, RABGGTB, GGPS1 | FNTA 4/4885FNTB 48/4885ALDH1A1 1782/4885 |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | FNTA 172/4885FNTB 1157/4885ALDH1A1 3039/4885 |
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | GGPS1, EBP, GGCT | FNTA 27/4885FNTB 322/4885ALDH1A1 1058/4885 |
| US-20120172453-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | API5, GAP43, GRN | FNTA 153/4885FNTB 1283/4885ALDH1A1 1413/4885 |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | UGP2, TGM2, GGCT | FNTA 316/4885FNTB 800/4885ALDH1A1 3952/4885 |
| US-20140275282-A1 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof | GGPS1, EBP, GGCT | FNTA 27/4885FNTB 322/4885ALDH1A1 1058/4885 |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | FNTA 172/4885FNTB 1157/4885ALDH1A1 3039/4885 |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | GGPS1, FNTA, GNPAT | FNTA 2/4885FNTB 6/4885ALDH1A1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.